Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | CTSV | O60911 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | NMT2 | O60551 | 1/20 | 0.41 |
| ▸ | NMT1 | P30419 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL925911 | 0.92 | PLA2G2A (0.42) | PLA2G2AMAOBMEN1KMT2AMAPT | |
| SCHEMBL12943041 | 0.87 | PLA2G2A (0.46) | PLA2G2ACTSLMEN1KMT2AMAPT | |
| SCHEMBL924463 | 0.87 | MEN1 (0.41) | PLA2G2AMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL4802002 | 0.85 | PLA2G2A (0.48) | PLA2G2AMMP13MAOBMEN1HSP90AA1 | |
| SCHEMBL924047 | 0.81 | PLA2G2A (0.51) | PLA2G2AKMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL923935 | 0.80 | MAPT (0.40) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL7105847 | 0.79 | MAPT (0.47) | MAOBMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL7047790 | 0.79 | MAPT (0.55) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL7531961 | 0.79 | PLA2G2A (0.48) | PLA2G2AMEN1HSP90AA1KMT2AMAPT | |
| SCHEMBL3034156 | 0.79 | PLA2G2A (0.48) | PLA2G2AMMP13KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1403254-B1 | Novel applications of acridinium compounds and derivatives in homogeneous assays | SIEMENS HEALTHCARE DIAGNOSTICS (US) | 2014-09-17 | — | — | EP | disclosed |
| US-7875467-B2 | Chemiluminescence; quantitative analysis of macromolecules; complexing sample to acridinium compound, labels for improving sensitivity of immunoassays, 2',6'-dimethyl-4'-N-succinimidyloxycaproyl-amidocarbonylphenyl-N10-2,7-tris[O-methoxyhexa(ethylene) glycol-sulfonamidylpropyl]-acridinium-9-carboxylate | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875467-B2 | Chemiluminescence; quantitative analysis of macromolecules; complexing sample to acridinium compound, labels for improving sensitivity of immunoassays, 2',6'-dimethyl-4'-N-succinimidyloxycaproyl-amidocarbonylphenyl-N10-2,7-tris[O-methoxyhexa(ethylene) glycol-sulfonamidylpropyl]-acridinium-9-carboxylate | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20090029349-A1 | Novel Applications of Acridinium Compounds and Derivatives in Homogeneous Assays | SIEMENS MEDICAL SOLUTIONS DIAGNOSTICS (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090029349-A1 | Novel Applications of Acridinium Compounds and Derivatives in Homogeneous Assays | SIEMENS MEDICAL SOLUTIONS DIAGNOSTICS (US) | 2009-01-29 | — | — | US | disclosed |
| US-20080305557-A1 | Novel Applications of Acridinium Compounds and Derivatives in Homogeneous Assays | SIEMENS MEDICAL SOLUTIONS DIAGNOSTICS (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080305557-A1 | Novel Applications of Acridinium Compounds and Derivatives in Homogeneous Assays | SIEMENS MEDICAL SOLUTIONS DIAGNOSTICS (US) | 2008-12-11 | — | — | US | disclosed |
| US-7319041-B2 | Applications of acridinium compounds and derivatives in homogeneous assays | SIEMENS MEDICAL SOLUTIONS DIAGNOSTIC (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319041-B2 | Applications of acridinium compounds and derivatives in homogeneous assays | SIEMENS MEDICAL SOLUTIONS DIAGNOSTIC (US) | 2008-01-15 | — | — | US | disclosed |
| US-20040063147-A1 | Novel applications of acridinium compounds and derivatives in homogeneous assays | BAYER CORPORATION | 2004-04-01 | — | — | US | disclosed |
| EP-1403254-A1 | Novel applications of acridinium compounds and derivatives in homogeneous assays | Bayer Healthcare, LLC (US) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063147-A1 | Novel applications of acridinium compounds and derivatives in homogeneous assays | ACR, SSB, NASP | PLA2G2A 2946/4885MMP13 4400/4885CTSV 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.